Use of tryptophan in combination with other antidepressant treatments: a review
- PMID: 1797098
- PMCID: PMC1188360
Use of tryptophan in combination with other antidepressant treatments: a review
Abstract
In four studies, all carried out more than 20 years ago, the combination of tryptophan plus a monoamine oxidase inhibitor was significantly better than tryptophan plus placebo in the treatment of depression. However, there is no evidence that tryptophan has any clinically significant effect on other treatments such as tricyclic antidepressants and ECT. Side effects of the combination of tryptophan and a monoamine oxidase inhibitors have limited the use of this combination. The risk of the serotonin syndrome is small, but it can occur. However, rapid cessation of tryptophan seems to avoid any long lasting adverse effects of the serotonin syndrome. In situations where enhancement of the therapeutic effect of monamine oxidase inhibitors outweighs the risk of adverse effects, the combination of tryptophan and a monoamine oxidase inhibitor is clinically useful. As the studies to date have looked at regular depressed patients, what is needed now is studies of this combination in therapy resistant depression.
Similar articles
-
Reversible monoamine oxidase-A inhibitors in resistant major depression.Clin Neuropharmacol. 1993;16 Suppl 2:S69-76. Clin Neuropharmacol. 1993. PMID: 8313400 Review.
-
Management of the depressive component of bipolar disorder.Depress Anxiety. 1996-1997;4(4):190-8. doi: 10.1002/(SICI)1520-6394(1996)4:4<190::AID-DA5>3.0.CO;2-J. Depress Anxiety. 1996. PMID: 9166651 Review.
-
Rational use of antidepressants.Prim Care. 1987 Dec;14(4):773-83. Prim Care. 1987. PMID: 3324134 Review.
-
Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.J Psychiatry Neurosci. 2000 Sep;25(4):337-46. J Psychiatry Neurosci. 2000. PMID: 11022398 Free PMC article. Clinical Trial.
-
Bipolar depression: treatment options.Can J Psychiatry. 1997 Aug;42 Suppl 2:87S-91S. Can J Psychiatry. 1997. PMID: 9288441 Review.
Cited by
-
The Role of Tryptophan Metabolites in Neuropsychiatric Disorders.Int J Mol Sci. 2022 Sep 1;23(17):9968. doi: 10.3390/ijms23179968. Int J Mol Sci. 2022. PMID: 36077360 Free PMC article. Review.
-
L-Tryptophan: Biochemical, nutritional and pharmacological aspects.Amino Acids. 1996 Mar;10(1):21-47. doi: 10.1007/BF00806091. Amino Acids. 1996. PMID: 24178430
-
Antidepressant failure: augmentation or substitution?J Psychiatry Neurosci. 1995 Jan;20(1):7-9. J Psychiatry Neurosci. 1995. PMID: 7865503 Free PMC article. No abstract available.
-
Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review.J Psychiatry Neurosci. 1992 Nov;17(5):206-14. J Psychiatry Neurosci. 1992. PMID: 1362653 Free PMC article. Review.
-
Genotype-dependent activity of tryptophan hydroxylase-2 determines the response to citalopram in a mouse model of depression.J Neurosci. 2005 Sep 7;25(36):8165-72. doi: 10.1523/JNEUROSCI.1816-05.2005. J Neurosci. 2005. PMID: 16148224 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials